What Can You Expect at the Premier Tumor Modeling Forum in the East Coast?
The oncology R&D landscape is transforming rapidly. Following the first IND supported by organoid only efficacy data from SillaJen and Qureator, alongside new FDA NAMs guidance and the Modernization Act 3.0, momentum to move beyond traditional animal models is accelerating. With the US oncology market projected to reach $211.78B by 2034 and the global tumor models market rising to $3.57B by 2030, demand for predictive, human relevant systems is soaring.
As the flagship, most established Tumor Models forum uniting the East Coast’s leading oncology drug developers, the 14th Tumor Models Summit Boston convenes experts shaping next generation model development and translational strategy.
Unmissable Event Highlights
Advancing TME Recapitulation to Strengthen Translatability in IO Combinations
Overcome the limitations of syngeneic and humanized mouse models by better recapitulating the tumor microenvironment to maximize model translational confidence for IO combination strategies with Johnson & Johnson
Enhancing ADC Predictability Through Multi Model Insights and Patient Relevant Biology
Probe the rationale behind leveraging patient-derived explant models and complementary tumor models to build a full picture for strategic ADC development and empower translation to the clinic with AbbVie
Building Predictive, TME Aligned 3D and Organ on Chip Models for Smarter Preclinical Decisions
Explore the development and robust validation of 3D tissue and organ-on-a-chip platforms that recapitulate the TME to power drug screening and guide mechanism-based therapeutic development with NCATS/NIH
AI Enabled Ex Vivo Insights to Shape Successful Bispecific Development
Validate the predictive power of a patient-derived ex vivo platform and AI foundational models by leveraging primary tumor material and ex vivo datasets to guide bispecific development and clinical strategy with AstraZeneca
Predictive Resistant Models to Clarify ADC Payload Performance and Optimize Patient Benefit
Develop resistant tumor models and define a translatable pharmacology strategy by combining patient relevant systems to evaluate novel ADC payloads and sharpen therapeutic differentiation for specific patient populations with Iksuda Therapeutics
Supercharging Tumoroid Platform Reliability to Drive Faster, Smarter Preclinical Decision Making
Spotlight verified strategies to build robust tumoroid platforms and demonstrate their translational value to accelerate drug screening and strengthen early preclinical decisions with Merck & Co.
What’s New for 2026?
86% new speakers from the leading East Coast oncology companies
8+ New Case Studies and Expertise Featuring Organoids, Organ-on-a-Chip, Ex Vivo Platforms & Computational Modelling
9+ New Case Studies and Expertise on Humanized In Vivo Model Development & Applications
12 New Companies Represented on the Expert Speaker Faculty
Divide & Conquer – Two Tracks, One Goal = Ensure Clinical Translation
Built with input from experts at AstraZeneca, Novartis, Takeda and more, the program has been specifically designed to address the key challenges at each stage of preclinical development.
By sending different members of the team across the two tracks, you can be sure you’ve left no stone unturned and have a team inspired with actionable takeaways to apply to their work.
A snapshot of key sessions featured in each track across the 2026 program include:
Tumor Model Applications in Drug Discovery & Screening
Selecting and Validating In Vitro, Complex In Vitro and In Vivo Models to Empower Target Identification, Evaluate Target Dependency and Ensure Robust Candidate Selection
- Jutta Deckert, VP, R&D Engineering & Technical, Iksuda Therapeutics
- Shanmugarajan Krishnan, Principal Scientist, Agenus
Tumor Model Applications for Efficacy Evaluation & Biomarker Discovery
Optimizing and Applying Humanized In Vivo, Computational and Ex Vivo Systems to Uncover MoA, Identify Underserved Patient Populations and Assess Combination Dosing Strategies
- Tony Arulanandam, Chief Executive Officer & Founder, Synaptimmune Therapeutics
- Lalit Kumar, Director, Clinical Bioanalytics & Translational Science, Beam Therapeutics
Explore the Full Event Guide
- Free* to attend for pharma & biotech
- Preview featured drug developer case studies on in vitro, in vivo, complex in vitro, ex vivo & more across multiple indications & novel modalities
- Explore dedicated, structured discussion sessions for unfiltered benchmarking with peers and model developers alike
- Unrivalled opportunities to network with preclinical and translational oncology experts from leading companies
- The East Coast’s longest standing meeting dedicated to the advances and best practices in tumor modeling for industry
Attending Companies Include
Explore the Agenda
Study the latest preclinical and translational data on tumor modeling and gain first-hand insight into model selection strategies for in vitro, in vivo, complex in vitro, ex vivo and more.
Partner With Us
Position yourself as the partner of choice amongst the leading East Coast biotech and pharmaceutical companies driving the future of oncology drug development.
Join East Coast Oncology Industry Experts
Connect with experts working across distinctive modalities and align on questions to progress translational decision-making.